Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Drug Office Reform: 'Everything' Is On The Table

Executive Summary

Deputy Office of New Drugs director says IND evaluation and post-market surveillance could be part of restructuring effort along with changes to application review.

You may also be interested in...



Industry Lauds, Worries About FDA Hiring Going Forward

Pfizer's Honig says that as the US FDA adds more employees or fills vacant positions, focus needs to be on training.

Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap

‘Better informed patients,’ ‘drug competition,’  ‘biosimilar innovation’ as well as nutrition and tobacco goals will be achieved through guidances, promotional plans and other items FDA will develop over the next year.

Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap

‘Better informed patients,’ ‘drug competition,’  ‘biosimilar innovation’ as well as nutrition and tobacco goals will be achieved through guidances, promotional plans and other items FDA will develop over the next year.

Related Content

Topics

UsernamePublicRestriction

Register

PS121970

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel